Boston Scientific reported its financial results for the first quarter of 2016.
GI & Endoscopy
Galmed Pharmaceuticals in New York has signed an investigator-initiated clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York to evaluate the effect of aramchol in combination with vitamin D for treatment of nonalcoholic fatty…
A study published in the American Journal of Gastroenterology found exercising may induce physiological changes that resemble gastroesophageal reflux disease, as reported by The Wall Street Journal.
Recently, with the FDA approval of Allergan's Viberzi and Valeant Pharmaceuticals' Xifaxan, as well as the low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet, there have been more alternatives available to people suffering from irritable bowel syndrome, according to…
David T. Rubin, MD, is a gastroenterologist and chief of the section of gastroenterology, hepatology and nutrition at the University of Chicago. He is also the Joseph B. Kirsner Professor of Medicine.
Advertisement
Here are the five most popular Becker's ASC Review gastroenterology and endoscopy stories for the week of April 25 to April 29.
The American Academy of Arts and Sciences elected John D. Carethers, MD, as a member, according to an AGA report.
Tobira Therapeutics announced results from a 12-week interim analysis of the Phase 2a ORION study.
EndoChoice appointed William Enquist as chairman of the board of directors.
A study published in the Journal of Pediatric Gastroenterology and Nutrition found newborns are likely being over treated the majority of the time with interventions, including surgery, for gastroesophageal reflux disease.